Background: The impact of recent guidelines for early detection and prevention of chronic kidney disease (CKD) on patient awareness of disease and factors that might be associated with awareness have not been well described.
C

HRONIC KIDNEY DISEASE
(CKD) is a growing problem in the United States, with an estimated prevalence of 9% to 12% in 1999 to 2000. 1, 2 However, the majority of persons with CKD, especially those in early stages, may be unaware of their disease. Although there have been recent efforts to increase awareness among health care providers by the dissemination of guidelines for the definition and staging of severity of CKD 3 and, more recently, among the public, 4 there is a lack of evidence about whether awareness of CKD has increased over time.
Better management of CKD can slow the progression of CKD, prevent complications, and reduce cardiovascularrelated outcomes. 3, 5, 6 Early referral to a nephrologist has been shown to improve outcomes for those who progress to endstage renal disease. 7 Even if quality improvement initiatives are accepted and implemented by the medical community, patients must still seek timely treatment to be exposed to these initiatives. However, because CKD in its early stages is usually silent and without remarkable symptoms, patients may not be aware of their disease. Even persons who have been identified as having early-stage CKD by evidence of kidney damage or reduced kidney function through regular screening may not understand their diagnosis or recognize the importance of treatment. Some patient characteristics may make screening more likely. For example, patients who are at high risk because of diabetes or hypertension may be screened more frequently. The likelihood of being aware could differ by age, sex, or race; for example, there is a greater prevalence of CKD among elderly patients, 1 ,2 but older patients may also be less likely to be screened or CKD may not be recognized in older patients because of competing health issues. Whether the patient is insured or has a regular health care provider could also affect CKD awareness. Finally, a healthy lifestyle (as indicated by such factors as no smoking, low alcohol intake, and high physical activity) may make a person less likely to have CKD but also more attentive to the presence of disease and the practice of preventive behaviors, which modify risk.
Previous studies have reported on static CKD awareness estimates in the US population in 1999-2000. 1, 8 To our knowledge, none have examined the trends in CKD awareness over time, with more recent data, nor have the associations of awareness with characteristics of persons with CKD been extensively explored. We sought to examine the prevalence of disease awareness among adults with CKD and the factors that may be associated with CKD awareness in a long-running, national survey of US citizens, the National Health and Nutrition Examination Survey (NHANES).
METHODS
STUDY DESIGN
The NHANES is currently conducted every 2 years by the National Center for Health Statistics to examine disease prevalence and trends over time in different cross-sectional representative samples of noninstitutionalized US civilian residents. The survey consists of a standardized in-home interview and a physical examination and blood and urine collection at a mobile examination center (MEC). Participants gave informed consent. 
MEASUREMENTS
Self-reported demographic characteristics (age, sex, race, and educational level), access to care (insurance, routine health care site, and time since last physician visit), lifestyle factors (smoking, physical activity, and alcohol use), and diagnoses (CKD, diabetes, and hypertension) were obtained during the interview portions of the surveys. Blood pressure was measured during the MEC visit, and the mean of all available measurements (up to 4) was used. Height and weight, used in the calculation of body mass index (BMI), were also measured during this examination. Random spot urine samples were obtained, and urine albumin and creatinine levels were measured using frozen specimens. Urine albumin level was measured using solid-phase fluorescence immunoassay; urine creatinine level was measured using the modified Jaffe kinetic method in the same laboratory. Serum creatinine level was measured by the modified kinetic method of Jaffe using different analyzers in different survey years.
DEFINITIONS
The outcome variable was awareness of CKD. Participants who answered "yes" to the question "Have you ever been told you have weak or failing kidneys (excluding kidney stones, bladder infections, or incontinence)?" during the interview were defined as being aware of their CKD. 12 Proteinuria was considered to be present at urinary albumin to creatinine ratios of 17:250 mg/g (microalbuminuria) and greater than 250 mg/g (macroalbuminuria) for men and 25:355 mg/g (microalbuminuria) and greater than 355 mg/g (macroalbuminuria) for women. 13 The independent variable of presence and stage of CKD in the participants was determined using eGFR and presence of proteinuria according to the Kidney Disease Outcomes Quality Initiative guidelines. 3 Because urine protein measurements in NHANES are cross-sectional, we did not have data on persistent proteinuria, and the definitions of stages were therefore modified as stage 1 (eGFR, Ͼ90 mL/ min/1.73 m 2 Other independent variables included sex, diabetes, and hypertension. Diabetes was defined by answer of "yes" to the question "Have you ever been told by a doctor that you have diabetes or sugar diabetes?"; hypertension was defined by an answer of "yes" to "Have you ever been told by a doctor that you have hypertension, also called high blood pressure?," a mean systolic blood pressure of 140 mm Hg or higher, or a mean diastolic blood pressure of 90 mm Hg or higher.
STATISTICAL METHODS
The proportion aware was calculated by CKD stage and survey year. Variance of proportions was estimated with Taylor series linearization. Exploration of factors associated with awareness was limited to CKD stage 3 because of small sample sizes for stage 4 and potential misclassification due to short-term variability in microalbuminuria in stages 1 and 2.
14 Proportion aware was calculated by patient characteristics and by year, and those characteristics that were shown or thought a priori to be associated with awareness were examined in logistic models predicting awareness by year.
All analyses were performed using the "SVY" commands in Stata version 9.2 (StataCorp, College Station, Texas) to account study design weights, strata, and pseudostrata. Appropriate NHANES 2-year and 6-year MEC weights (WTMEC) were used; 6-year weights were calculated as the following: 
RESULTS
PROPORTION OF PERSONS WITH CKD WHO ARE AWARE OF THEIR DISEASE
Overall, there were 2992 NHANES participants with CKD stages 1 to 4 who met the inclusion criteria ( 
FACTORS ASSOCIATED WITH CKD AWARENESS IN THOSE WITH CKD STAGE 3
A total of 1314 participants had CKD stage 3 from 1999 to 2004; of these, 7.8% were aware of their CKD (Table) . Participants with CKD stage 3 who were nonHispanic black or Mexican American had higher rates of awareness than participants of non-Hispanic white or other races. A greater proportion of men were aware of their CKD compared with women. Chronic kidney disease awareness was far greater, but still less than onefifth, among participants who had proteinuria, diabetes, hypertension, and obesity compared with those who did not. Those with less education and those with a routine site for health care were also more likely to be aware of their CKD, but these associations were not statistically significant. Within individual survey years, the associations of awareness with patient characteristics were generally similar to those seen in the overall study period (Table) , although statistical significance was often lost in these small subgroups. For example, male sex was associated with increased awareness for all years, but the association was only statistically significant for 1999-2000. The association of CKD awareness with proteinuria in these stage 3 participants was statistically significant for all 3 survey year periods, with macroalbuminuria being far more predictive than microalbuminuria. Diabetes and hypertension were statistically significantly associated with CKD awareness in 2001-2002 and 2003-2004 only. In adjusted models, male sex, proteinuria, diabetes, and hypertension were all statistically significantly associated with greater odds of CKD awareness (Figure 4) . Older age was associated with less awareness overall, and black race was associated with more awareness; however, the associations were not statistically significant. The increase in awareness over time can be seen in both the younger and older and white and black subgroups ( Figure 4A and B) . Similarly, awareness increased in men and women from 1999 to 2002, but men remained more likely to be aware in all 3 survey year periods ( Figure 4C ). Regardless of proteinuria subgroup ( Figure 4D ), awareness increased after 1999-2001, with macroalbuminuria being a greater predictor than microalbuminuria in all 3 survey year periods. The same trend was seen for diabetes ( Figure 4E ), with awareness increasing over time and diabetic individuals remaining more likely to be aware. Hypertensive participants were more likely to be aware, especially in the last 2 survey year periods, but it is unclear whether awareness increased in nonhypertensive participants ( Figure 4F ) have not produced high levels of awareness among patients since their implementation several years ago. However, changes in guidelines, 3 coupled with recent increased reporting of eGFR, 16 may be at least partially responsible for differential increase in awareness for CKD stage 3 vs stages 1 and 2. Chronic kidney disease stages 1 and 2 are identified through the presence of proteinuria, which may not be as commonly, or consistently, detected.
Chronic kidney disease awareness rates, at lower than 10% for CKD stage 3 and lower than 50% for CKD stage 4, are still unacceptably low. The discrepancy between CKD awareness and awareness of other chronic diseases is large. Patients with hypertension and diabetes had awareness rates of 74% and 70%, respectively, in the same population during the same period. 18, 19 Both the National High Blood Pressure Education Program of the National Heart, Lung, and Blood Institute, founded in 1972, 20 and the National Diabetes Education Program (through the combined efforts of the National Institutes of Health, Centers for Disease Control and Prevention, and more than 200 private organizations), founded in 1997, 21 ran aggressive public awareness campaigns for many years. Similar long-term, broad-scale efforts in CKD might increase awareness dramatically in the United States, especially if they target both practitioners, who could identify and treat affected individuals, 7, 22 as well as high-risk individuals, who could present to practitioners based on their knowledge of CKD. Given that CKD not only can result in progression to end-stage renal disease and dependence on dialysis and transplantation but also is an independent risk factor for cardiovascular disease and mortality, 23, 24 the importance of increasing CKD awareness should not be underestimated.
Awareness was greater among some subgroups of patients. Black participants with CKD were more likely to be aware of their disease than white participants. This race differential in patient awareness may reflect patient and physician perception of black race as a risk factor for CKD 25 or greater family history among these patients, 26 which may result in more testing among these patients. Increased physician awareness of black race as a risk factor and greater communication of this risk to these patients may also have contributed to the greater CKD awareness seen in black patients. Although older patients are at increased risk for reduced kidney function and CKD, they were less likely to be aware of their disease. Whether this reflects less testing or acceptance of reduced kidney function on the part of the practitioners as a normal part of aging in this population is unknown. Also, although there is no evidence that men are at higher risk of developing CKD than women, 27 men were far more likely to be aware of their CKD. Higher awareness among men may also be due to their higher serum creatinine levels, which physicians, especially those who are less aware of CKD and who use creatinine levels alone rather than age-and sex-adjusted eGFR, may recognize more readily as an abnormality. Physicians may also perceive men to be at higher risk than women and thus screen for CKD more often in these patients; or men's symptoms of CKD may be more pronounced or less likely to be attributed to other causes than women's symptoms.
Several clinical conditions made CKD awareness more likely as well. Those with hypertension and diabetes were far more likely to be aware of their disease. This greater likelihood may be because physicians recognize that these patients are at much greater risk for CKD. Patient awareness of their risk may also encourage patients to ask for CKD screening. In addition, these patients are more likely to be seen frequently and thus be subjected to urine and blood testing as part of their regular care, making it more likely for CKD to be detected.
We expected that better access to care might lead to higher rates of disease awareness. However, we found no association between having health insurance and CKD awareness. This suggests that, even when patients have access to care, physician communication of risk and/or patient uptake of the information presented may be inadequate. Having a routine site for health care was marginally associated with greater CKD awareness, after adjustment for other factors. This may be because those at greatest risk, including those with diabetes and hypertension, are more likely to have a routine site for health care because of the condition that puts them at risk for CKD. Given that having a routine site was associated with awareness after adjustment for these conditions, but that merely having health insurance was not, it is also possible that having an established relationship with a health care provider is more important for generating awareness than general access to care. Further efforts to enhance the patient-provider relationship, in the context of discussion of CKD, may improve awareness. Finally, we found that lifestyle factors, such as obesity, physical activity, smoking, and alcohol use, were not associated with CKD awareness.
The urgency of making patients aware of CKD could be questioned on the grounds that many patients die before they progress to a more severe stage of CKD and many are already being treated for diabetes and/or hypertension. 28, 29 However, there are still compelling reasons why patients would benefit from awareness of their CKD. First, they could be made aware of medication exposures that could influence progression, including over-thecounter nonsteroidal anti-inflammatory agents and contrast agents used in imaging tests. In addition, there is evidence that appropriate early treatment (with medications and hypertension control) could slow progression of CKD. 29 Also, patients should be aware that current and future medications could require dose adjustment in the setting of CKD. Many conditions, such as heart disease and cognitive decline, may increase with severity of CKD, and awareness of disease may motivate patients to adopt preventive strategies for these conditions. Awareness might also make patients more vigilant with adherence to dietary recommendations for comorbid hypertension and diabetes, including lower salt, sugar, and fat intake, as well as other lifestyle changes.
There are several limitations to this study that deserve mention. First, the questionnaire item assessing awareness asked participants if they had ever been told they had weak or failing kidneys. Patients may not be told that their kidneys are weak or failing, especially in earlystage CKD; rather, they may be told that they have decreased kidney function or protein in the urine. Thus, there is the possibility of misinterpretation of the questionnaire item by the participants; 1% of respondents without kidney disease answered "yes" to this question, indicating a small amount of misclassification of participant awareness and/or of early-stage disease. Second, proteinuria was a single measurement with no follow-up in NHANES, and CKD in its early stages is defined as persistent proteinuria. This lack of a confirmatory urine protein sample may have led to misclassification of participants with CKD stages 1 and 2. In fact, only 63% of subjects with albuminuria at the first visit in NHANES III had albuminuria at the second visit.
14 Misclassification of disease may have also occurred due to GFR estimation. In addition, we do not know the duration of reduced kidney function and/or proteinuria, nor do we know the duration of symptoms, if any, that may have led the participant to seek medical treatment. The small number of participants with CKD, especially in single surveys, was another limitation. Health care provider factors, especially provider knowledge of CKD, quality of patient-provider communication, and specialist referral, may play a significant role in CKD awareness but could not be assessed using these data.
Despite substantial recent efforts, both nationally and locally, to increase awareness of CKD in the community, the majority of those with CKD, as defined by decreased renal function and/or evidence of kidney damage, do not recall having been told by a physician that they have CKD. Renewed and greater efforts and resources may need to be directed toward dissemination activities by the government (eg, Centers for Disease Control and Prevention and National Kidney Disease Education Program) and private organizations (eg, National Kidney Foundation, American Society of Nephrology, Renal Physicians Association, and American College of Physicians) to increase awareness of CKD among practitioners and in the general community. Not only those with risk factors (eg, diabetes and hypertension) but also those who are less likely to be aware, including older, female, and white patients, without diabetes or hypertension, and those without routine access to health care should be targeted more aggressively. Future studies of disease awareness among those with CKD should focus on intervention by examining patient, health care provider, and societal (eg, public relations campaigns) factors that lead to better CKD awareness.
